Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

MONDO:0015164

Also known as:AML and myelodysplastic syndromes related to alkylating agent

Overview

Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent is a subgroup of therapy-related myeloid neoplasms (t-MN), associated with a treatment of an unrelated neoplastic or autoimmune disease with cytotoxic agents, like cyclophosphamid, platins, melphalan and others. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. It usually presents with multilineage dysplasia and cytopenias 5-10 years after exposure, with symptoms related to the degree of bone marrow failure and the corresponding cytopenia (fatigue, bleeding and bruising, recurrent infections, bone pain).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent.

12 publications have been identified in PubMed for acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent. Research spans Case Report / Case Series (58%), Clinical Trial Publication (33%), and Basic Science / Preclinical (8%).

Research Type	Count	% of Total
Patient case studies	7	58%

Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:36 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Financial & Access Support (External Programs)

View all programs →

Acute Myeloid Leukemia Fund

Premium/CopayCurrently AcceptingOperated by HealthWell Foundation

Visit official site

Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.

Are you a patient organization for this condition?

Claim this page and your organization will be listed here for patients and families to find.

Be recognized as the official organization
Get notified of new trials, FDA decisions, and research
Appear in the disease page directory
Embed this content on your website — free

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:102379

GARD

Genetic and Rare Diseases Info Center

GARD:19835

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Overview

Research Landscape

Patient Support

Financial & Access Support (External Programs)

Are you a patient organization for this condition?

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications